Perioperative Polychemotherapy for Gastric Cancer
Keywords:
gastric cancer, perioperative chemotherapy, neoadjuvant therapy, adjuvant therapy, polychemotherapy, survival, meta-analysisAbstract
Gastric cancer remains one of the leading causes of cancer-related mortality worldwide. Despite advances in surgical techniques, treatment outcomes remain unsatisfactory due to the high rate of recurrence and metastasis. In recent decades, perioperative polychemotherapy, including neoadjuvant and adjuvant treatment, has become increasingly important. The aim of this work is to analyze the effectiveness, safety, and modern approaches to perioperative polychemotherapy in gastric cancer. Clinical trial data and meta-analyses demonstrating improvements in overall and disease-free survival with this approach are reviewed. Special attention is given to modern treatment regimens and the prospects of combination therapy with immunotherapy.
Downloads
Published
Issue
Section
How to Cite
References
Wei C., Du X., Hu J. et al. Perioperative chemotherapy versus adjuvant chemotherapy in gastric cancer // Crit Rev Oncol Hematol. – 2024. – Vol. 198. – P. 104082.
Ou H., Zhuang J., Jian M. et al. Perioperative versus adjuvant chemotherapy // Frontiers in Oncology. – 2025. – Vol. 15. – P. 1432596.
Zhao J.H. et al. Meta-analysis of perioperative chemotherapy // BMC Cancer. – 2016. – Vol. 16. – P. 1-10.
Bakhniuk K.D. Perioperative chemotherapy for gastric cancer // Practical Oncology. – 2021. – Vol. 4(1). – P. 15-22.
Serrano Uson P.L. et al. Docetaxel perioperative chemotherapy // Scientific Reports. – 2019. – Vol. 9. – P. 15806.
Impact of perioperative chemotherapy in gastric cancer // PMC. – 2022. – P. 1-8.
Perioperative chemotherapy prolongs survival // Nat Rev Gastroenterology. – 2006. – Vol. 3. – P. 599.
Perioperative chemoimmunotherapy meta-analysis // Oxford Academic. – 2026. – P. 1-12.
